STATES 2.0 Act
- Sponsor
- Rep. Joyce, David P. [R-OH-14]
- Committees
- Transportation and Infrastructure Committee (primary)
- Last action
- Apr 17, 2025
Bottom line
The STATES 2.0 Act defers federal marijuana enforcement to states and federally recognized Indian Tribes that have legalized cannabis, while establishing federal oversight for interstate commerce and product safety through the FDA.
What it actually does
This bill significantly alters federal marijuana policy by exempting state-legal marijuana activities from most provisions of the Controlled Substances Act. It establishes a framework for interstate transportation of marijuana between states where it is legal and grants the Food and Drug Administration (FDA) authority to regulate marijuana products, similar to how it regulates alcohol-containing foods or other consumer products. The bill also mandates a study on marijuana legalization's effects on traffic safety and clarifies that compliant activities are not subject to federal drug trafficking or forfeiture laws, nor the IRS 280E tax code provision.
Proponents argue
Proponents argue that the bill upholds the Tenth Amendment by empowering states to determine their own cannabis policies, thereby respecting diverse community values. They contend that a federal framework for interstate commerce and product regulation will help displace the illicit market, improve public safety by allowing law enforcement to focus on more serious crimes, and create a more rational tax structure for legal businesses, fostering economic growth and consumer safety.
Opponents contend
Opponents express concerns that loosening federal restrictions on marijuana, even with state-level control, could lead to increased rates of marijuana use, particularly among youth, and potentially exacerbate public health issues. They may also raise questions about the effectiveness of state-level regulation in preventing diversion to illicit markets or addressing impaired driving, despite the bill's provisions for FDA oversight and a traffic safety study.
The bill is relatively concise for its significant policy implications, allowing an informed reader to grasp its core provisions within a reasonable timeframe.
Section 4, Part G of the Controlled Substances Act
Federal Non-Application to State-Legal Marijuana
This section amends the Controlled Substances Act (CSA) to state that its provisions, as applied to marijuana, generally will not apply to marijuana manufactured, produced, possessed, distributed, dispensed, administered, or delivered in compliance with state or federally recognized Indian Tribe law. This effectively removes federal criminal penalties for marijuana activities that are legal under state or tribal jurisdiction, with specific exceptions for certain serious offenses.
Supporters argue
Supporters argue this provision is crucial for upholding states' rights and allowing local communities to determine their own policies regarding cannabis without federal interference. They contend it will bring clarity and stability to the legal cannabis industry.
Critics contend
Critics may argue that this provision could lead to a patchwork of regulations across the country, making federal oversight challenging and potentially increasing public health and safety risks if state laws are perceived as too permissive.
Tradeoffs
The provision balances state sovereignty with the historical federal role in drug control. It aims to resolve the conflict between state and federal marijuana laws but introduces complexities in federal regulatory oversight.
Section 4(c), Part G of the Controlled Substances Act
Interstate Transportation of Marijuana
This provision prohibits any state or Indian Tribe from blocking the transportation or shipment of marijuana through its territory if both the originating and destination states or territories permit marijuana activities. It also exempts persons engaged in such interstate transportation from most CSA provisions, provided the transport is between two states where marijuana is legal.
Section 4(f), Part G of the Controlled Substances Act
Removal of Marijuana from Schedule for Compliant Activities
This section mandates that for the purposes of the Controlled Substances Act, marijuana manufactured, produced, possessed, distributed, dispensed, administered, or delivered in compliance with state or federally recognized Indian Tribe law shall be deemed a substance that does not meet the requirements for inclusion in any schedule. It further requires the Attorney General to finalize a rule executing this descheduling within 180 days of the Act's enactment.
Section 7
Regulation of Marijuana Products by Food and Drug Administration
This section grants the FDA authority to regulate marijuana products. Marijuana products meeting the definition of a drug or cosmetic will be treated as such under the Federal Food, Drug, and Cosmetic Act (FDCA). For marijuana products that are food or dietary supplements, the FDA will have authority similar to its regulation of food containing alcohol. For other marijuana products, the FDA must promulgate regulations within 180 days covering contaminant testing, manufacturing practices, and marketing, with special attention to youth prevention, but without requiring premarket approval. It also prohibits marketing marijuana products in combination with drugs, biological products, devices, tobacco products, or alcohol products.
Section 9
Rule of Construction for Compliant Conduct
This section clarifies that conduct in compliance with the Act and its amendments shall not be considered unlawful, drug trafficking, a basis for property forfeiture, or subject to Section 280E of the Internal Revenue Code (which disallows tax deductions for businesses trafficking in controlled substances). Furthermore, proceeds from compliant transactions will not be deemed proceeds of an unlawful transaction under federal money laundering statutes.
Mandates the Attorney General to finalize a rule within 180 days of enactment to formally deschedule marijuana for activities compliant with state or tribal law.
Section 4(f)(2)
Why it matters:This is standard legislative practice to include specific implementation directives within the relevant policy section, rather than in a separate administrative title.
Case for: Supporters argue this ensures timely and definitive federal action to align the Controlled Substances Act with the new policy, providing certainty for states, tribes, and the industry.
Case against: Critics might express concern about the speed of this mandate, suggesting that 180 days may be insufficient for a thorough administrative review and rulemaking process for such a significant change.
Estimated impact: This provision triggers a mandatory administrative process that will formally alter the legal status of compliant marijuana activities under federal law, impacting all federal agencies involved in drug enforcement and regulation.
Exempts persons at least 18 years of age from federal penalties for distributing *medicinal* marijuana to persons under 21, provided it complies with Section 710 (state/tribal law compliance).
Section 6(c)
Why it matters:This is a technical amendment to an existing statute, a common legislative drafting technique to integrate new policy into existing legal frameworks.
Case for: Proponents argue this is a necessary provision to ensure that minors with legitimate medical needs can access medicinal marijuana under state-regulated programs without federal criminalization for their caregivers or dispensaries.
Case against: Opponents might raise concerns that any provision allowing distribution of marijuana to minors, even medicinal, could create loopholes or send mixed messages about youth access, potentially increasing risks.
Estimated impact: This provision specifically protects medical marijuana providers and patients under 21 in states with legal medical cannabis programs from federal prosecution for distribution to minors.
States that the FDA regulation for 'other' marijuana products (those not classified as drugs, food, dietary supplements, or cosmetics) shall *not* require premarket approval.
Section 7(e)(4)
Why it matters:This is a specific regulatory instruction, often placed within the detailed framework of agency mandates.
Case for: Industry proponents would argue this is vital for fostering innovation and reducing regulatory burdens, allowing new products to enter the market more quickly without extensive and costly pre-approval processes.
Case against: Public health advocates might contend that the absence of premarket approval could pose risks, as products might reach consumers without a comprehensive safety review, potentially leading to unforeseen health consequences.
Estimated impact: This provision significantly impacts the regulatory pathway and market entry for a broad category of marijuana products, potentially accelerating product development but also shifting the burden of proof for safety to post-market surveillance.